Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Article Details
Authors
Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi
Article Type
Erratum
DOI
10.7573/dic.2021-6-8
Related Articles
- The non-anticoagulation costs of atrial fibrillation management: findings from an observational study in NHS Primary Care
- Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
- Multifocal infantile haemangiomatosis with hepatic involvement: two cases and treatment management
Article Page
AbstractThe authors wish to make the following corrections to their article:
Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs in Context 2021; 10: 2021-2-6. DOI: 10.7573/dic.2021-2-6
Download free full text PDF
